{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:29:48Z","timestamp":1790958588879,"version":"4.1.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000985","name":"Assisi Foundation of Memphis Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000985","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012524","name":"ALSAC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012524","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.xcrm.2024.101422","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T15:26:45Z","timestamp":1707751605000},"page":"101422","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Peptide-scFv antigen recognition domains effectively confer CAR T\u00a0cell multiantigen specificity"],"prefix":"10.1016","volume":"5","author":[{"given":"Jaquelyn T.","family":"Zoine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalyan","family":"Immadisetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Ibanez-Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Nevitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Unmesha","family":"Thanekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqing","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas","family":"Karouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Chockley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bright","family":"Arthur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Sheppard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffery M.","family":"Klco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna M.","family":"Langfitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giedre","family":"Krenciute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Gottschalk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Madan","family":"Babu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Paulina","family":"Velasquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2024.101422_bib1","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1158\/1078-0432.CCR-18-2743","article-title":"FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma","volume":"25","author":"Bouchkouj","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101422_bib2","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1158\/1078-0432.CCR-18-2035","article-title":"FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia","volume":"25","author":"O'Leary","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101422_bib3","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/1078-0432.CCR-18-2337","article-title":"FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease","volume":"25","author":"Jen","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101422_bib4","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature10738","article-title":"Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing","volume":"481","author":"Ding","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2024.101422_bib5","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","article-title":"Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML","volume":"33","author":"Haubner","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2024.101422_bib6","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41568-019-0230-9","article-title":"The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML","volume":"20","author":"Vetrie","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2024.101422_bib7","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nature22993","article-title":"Tracing the origins of relapse in acute myeloid leukaemia to stem cells","volume":"547","author":"Shlush","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2024.101422_bib8","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-019-0170-3","article-title":"Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?","volume":"9","author":"Yilmaz","year":"2019","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.xcrm.2024.101422_bib9","doi-asserted-by":"crossref","DOI":"10.1007\/s11864-020-00765-5","article-title":"Treatment of Relapsed Acute Myeloid Leukemia","volume":"21","author":"Thol","year":"2020","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.xcrm.2024.101422_bib10","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.bbmt.2012.10.021","article-title":"Chimeric antigen receptor--modified T\u00a0cells: clinical translation in stem cell transplantation and beyond","volume":"19","author":"Riddell","year":"2013","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.xcrm.2024.101422_bib11","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2024.101422_bib12","doi-asserted-by":"crossref","DOI":"10.4161\/onci.27214","article-title":"Acute myeloid leukemia therapeutics: CARs in the driver's seat","volume":"2","author":"Mardiros","year":"2013","journal-title":"OncoImmunology"},{"key":"10.1016\/j.xcrm.2024.101422_bib13","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1182\/blood-2013-09-529537","article-title":"Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T\u00a0cells","volume":"123","author":"Gill","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101422_bib14","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1038\/s41375-021-01232-2","article-title":"Autologous CD33-CAR-T cells for treatment of relapsed\/refractory acute myelogenous leukemia","volume":"35","author":"Tambaro","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2024.101422_bib15","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.omtm.2020.06.024","article-title":"The Art and Science of Selecting a CD123-Specific Chimeric Antigen Receptor for Clinical Testing","volume":"18","author":"Riberdy","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.xcrm.2024.101422_bib16","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1038\/s41467-022-29668-9","article-title":"Allogeneic TCR\u03b1\u03b2 deficient CAR T-cells targeting CD123 in acute myeloid leukemia","volume":"13","author":"Sugita","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2024.101422_bib17","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1038\/s41467-022-29669-8","article-title":"Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T\u00a0cells","volume":"13","author":"Cai","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2024.101422_bib18","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.V130.Suppl_1.811.811","article-title":"Remissions of Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm Following Treatment with CD123-Specific CAR T Cells: A First-in-Human Clinical Trial","volume":"130","author":"Budde","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101422_bib19","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41467-022-28243-6","article-title":"CAR T\u00a0cells redirected to cell surface GRP78 display robust anti-acute myeloid leukemia activity and do not target hematopoietic progenitor cells","volume":"13","author":"Hebbar","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2024.101422_bib20","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1158\/1535-7163.MCT-15-0774","article-title":"Expression of GRP78, Master Regulator of the Unfolded Protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma","volume":"15","author":"Gifford","year":"2016","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.xcrm.2024.101422_bib21","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3389\/fnins.2017.00177","article-title":"GRP78 at the Centre of the Stage in Cancer and Neuroprotection","volume":"11","author":"Casas","year":"2017","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.xcrm.2024.101422_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/children7020014","article-title":"Harnessing T Cells to Target Pediatric Acute Myeloid Leukemia: CARs, BiTEs, and Beyond","volume":"7","author":"Epperly","year":"2020","journal-title":"Children"},{"key":"10.1016\/j.xcrm.2024.101422_bib23","first-page":"98","article-title":"CD123 (interleukin 3 receptor alpha chain)","volume":"15","author":"Moretti","year":"2001","journal-title":"J.\u00a0Biol. Regul. Homeost. Agents"},{"key":"10.1016\/j.xcrm.2024.101422_bib24","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ccell.2017.09.004","article-title":"Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML","volume":"32","author":"Perna","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2024.101422_bib25","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1182\/blood-2022-170201","article-title":"Safety and Anti-Leukemic Activity of CD123-CAR T Cells in Pediatric Patients with AML: Preliminary Results from a Phase 1 Trial","volume":"140","author":"Naik","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101422_bib26","article-title":"To go or not to go? Biological logic gating engineered T\u00a0cells","volume":"10","author":"Abbott","year":"2022","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2024.101422_bib27","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13045-020-00856-8","article-title":"Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia","volume":"13","author":"Dai","year":"2020","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2024.101422_bib28","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","article-title":"T Cells Expressing CD19\/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells","volume":"4","author":"Zah","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.xcrm.2024.101422_bib29","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1038\/s41467-020-16160-5","article-title":"Systematically optimized BCMA\/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma","volume":"11","author":"Zah","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2024.101422_bib30","first-page":"66","article-title":"B7-H3 role in the immune landscape of cancer","volume":"6","author":"Castellanos","year":"2017","journal-title":"Afr. J. Clin. Exp. Immunol."},{"key":"10.1016\/j.xcrm.2024.101422_bib31","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-20-2540","article-title":"Preclinical Evaluation of B7-H3-specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia","volume":"27","author":"Lichtman","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101422_bib32","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba1786","article-title":"Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling","volume":"372","author":"Weber","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2024.101422_bib33","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/s41586-021-03828-1","article-title":"Highly accurate protein structure prediction for the human proteome","volume":"596","author":"Tunyasuvunakool","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2024.101422_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092523","article-title":"Bispecific Chimeric Antigen Receptor T Cell Therapy for B Cell Malignancies and Multiple Myeloma","volume":"12","author":"Cronk","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.xcrm.2024.101422_bib35","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","article-title":"T Cells Expressing CD19\/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells","volume":"4","author":"Zah","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.xcrm.2024.101422_bib36","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1093\/neuonc\/nox182","article-title":"Trivalent CAR T\u00a0cells overcome interpatient antigenic variability in glioblastoma","volume":"20","author":"Bielamowicz","year":"2018","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.xcrm.2024.101422_bib37","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.omto.2018.10.006","article-title":"Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22","volume":"11","author":"Qin","year":"2018","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.xcrm.2024.101422_bib38","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T\u00a0cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2024.101422_bib39","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41591-021-01497-1","article-title":"CAR T\u00a0cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial","volume":"27","author":"Cordoba","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2024.101422_bib40","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.ymthe.2021.08.033","article-title":"A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL","volume":"30","author":"Zanetti","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2024.101422_bib41","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1172\/JCI87366","article-title":"Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies","volume":"126","author":"Ruella","year":"2016","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.xcrm.2024.101422_bib42","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature10738","article-title":"Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing","volume":"481","author":"Ding","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2024.101422_bib43","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/j.ccell.2023.09.010","article-title":"Cooperative CAR targeting to selectively eliminate AML and minimize escape","volume":"41","author":"Haubner","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2024.101422_bib44","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1158\/1535-7163.MCT-17-1097","article-title":"Strategies to Address Chimeric Antigen Receptor Tonic Signaling","volume":"17","author":"Ajina","year":"2018","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.xcrm.2024.101422_bib45","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/978-1-0716-0146-4_17","article-title":"Analysis of CAR-Mediated Tonic Signaling","volume":"2086","author":"Calderon","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.xcrm.2024.101422_bib46","doi-asserted-by":"crossref","first-page":"7396","DOI":"10.1182\/blood-2022-170503","article-title":"LigandCD70.CAR As a Platform for Dual-Targeting CAR T Cells for Acute Myeloid Leukemia","volume":"140","author":"Scherer","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101422_bib47","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood-2018-99-110579","article-title":"First-in-Human CLL1-CD33 Compound CAR T Cell Therapy Induces Complete Remission in Patients with Refractory Acute Myeloid Leukemia: Update on Phase 1 Clinical Trial","volume":"132","author":"Liu","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101422_bib48","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood-2020-143474","article-title":"Tandem CD19\/CD22 Dual Targets CAR-T Cells Therapy Acquires Superior CR Rate Than CD19 CAR-T Cells: A Case Controlled Study","volume":"136","author":"Cui","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101422_bib49","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/sj.leu.2401903","article-title":"The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells","volume":"14","author":"Jordan","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2024.101422_bib50","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/j.celrep.2018.10.055","article-title":"KDEL Receptors Are Differentially Regulated to Maintain the ER Proteome under Calcium Deficiency","volume":"25","author":"Trychta","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2024.101422_bib51","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1714866115","article-title":"Endoplasmic reticulum stress activates SRC, relocating chaperones to the cell surface where GRP78\/CD109 blocks TGF-\u03b2 signaling","volume":"115","author":"Tsai","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2024.101422_bib52","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/tpj.2017.46","article-title":"Therapeutic targeting of membrane-associated GRP78 in leukemia and lymphoma: preclinical efficacy in\u00a0vitro and formal toxicity study of BMTP-78 in rodents and primates","volume":"18","author":"Staquicini","year":"2018","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.xcrm.2024.101422_bib53","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1038\/mt.2016.116","article-title":"CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia","volume":"24","author":"Bonifant","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2024.101422_bib54","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1182\/blood-2012-12-474056","article-title":"T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia","volume":"122","author":"Mardiros","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101422_bib55","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.3324\/haematol.2021.279301","article-title":"Improving the anti-acute myeloid leukemia activity of CD123-specific engager T\u00a0cells by MyD88 and CD40 costimulation","volume":"108","author":"Vaidya","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.xcrm.2024.101422_bib56","doi-asserted-by":"crossref","first-page":"7376","DOI":"10.1182\/blood-2022-169800","article-title":"Establishing Immunocompetent Leukemia Models to Investigate the Impact of CAR T Cells on the Immune Microenvironment and Bone Marrow Niche","volume":"140","author":"Moore","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101422_bib57","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.V130.Suppl_1.811.811","article-title":"Remissions of Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm Following Treatment with CD123-Specific CAR T Cells: A First-in-Human Clinical Trial","volume":"130","author":"Budde","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101422_bib58","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1182\/blood-2022-169928","article-title":"Ameli-01: A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R\/R) CD123+ Acute Myeloid Leukemia (AML)","volume":"140","author":"Sallman","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101422_bib59","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1038\/mtna.2013.32","article-title":"TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy","volume":"2","author":"Grada","year":"2013","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.xcrm.2024.101422_bib60","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1038\/s41467-020-17175-8","article-title":"Tumor response and endogenous immune reactivity after administration of HER2 CAR T\u00a0cells in a child with metastatic rhabdomyosarcoma","volume":"11","author":"Hegde","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2024.101422_bib61","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2024.101422_bib62","article-title":"Bringing TrackMate in the era of machine-learning and deep-learning","author":"Ershov","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.xcrm.2024.101422_bib63","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1002\/imt2.43","article-title":"Complex heatmap visualization","volume":"1","author":"Gu","year":"2022","journal-title":"iMeta"},{"key":"10.1016\/j.xcrm.2024.101422_bib64","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","article-title":"VMD: visual molecular dynamics","volume":"14","author":"Humphrey","year":"1996","journal-title":"J.\u00a0Mol. Graph."},{"key":"10.1016\/j.xcrm.2024.101422_bib65","series-title":"Gnuplot 4.5: an interactive plotting program","author":"Williams TaK","year":"2011"},{"key":"10.1016\/j.xcrm.2024.101422_bib66","doi-asserted-by":"crossref","first-page":"9434","DOI":"10.1021\/bi060264j","article-title":"Targeting heat shock proteins on cancer cells: selection, characterization, and cell-penetrating properties of a peptidic GRP78 ligand","volume":"45","author":"Kim","year":"2006","journal-title":"Biochemistry"},{"key":"10.1016\/j.xcrm.2024.101422_bib67","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/mt.2009.133","article-title":"Immunotherapy for osteosarcoma: genetic modification of T\u00a0cells overcomes low levels of tumor antigen expression","volume":"17","author":"Ahmed","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2024.101422_bib68","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.ymthe.2017.01.011","article-title":"Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells","volume":"25","author":"Diaconu","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2024.101422_bib69","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.omto.2020.06.018","article-title":"Route of 41BB\/41BBL Costimulation Determines Effector Function of B7-H3-CAR.CD28\u03b6 T Cells","volume":"18","author":"Nguyen","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.xcrm.2024.101422_bib70","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat. Methods"}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124000454?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124000454?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T11:00:56Z","timestamp":1733223656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379124000454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S2666379124000454"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101422","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peptide-scFv antigen recognition domains effectively confer CAR T\u00a0cell multiantigen specificity","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101422","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s).","name":"copyright","label":"Copyright"}],"article-number":"101422"}}